Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 19 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

6%

1 of 17 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (11)
P 1 (2)

Trial Status

Completed17
Recruiting1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT06489717Not ApplicableCompletedPrimary

High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m)

NCT06489691Not ApplicableCompletedPrimary

High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m)

NCT06489743Not ApplicableCompletedPrimary

Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)

NCT06489704Not ApplicableCompletedPrimary

High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)

NCT06489756Not ApplicableCompletedPrimary

Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)

NCT06852924Not ApplicableRecruitingPrimary

Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE)

NCT06489730Not Yet RecruitingPrimary

HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

NCT05131737Not ApplicableCompletedPrimary

Exercise Endurance Time on the 2nd Day at 2500 m High Altitude

NCT05264324Not ApplicableCompletedPrimary

Maximal Exercise Capacity at 2500 m of High Altitude

NCT05089487Not ApplicableCompletedPrimary

Nocturnal Oxygenation and Sleep-related Breathing Disorders During the First Night of a Stay at 2500m of High Altitude in Patients With Precapillary Pulmonary Hypertension

NCT05112172Not ApplicableCompletedPrimary

Effect of Oxygen Therapy for Patients With Precapillary Pulmonary Hypertension Who Experience an Altitude Related Adverse Health Effect (ARAHE) During 30h Exposure to 2500m

NCT05107700Not ApplicableCompletedPrimary

Altitude Related Adverse Health Effects (ARAHE) in Patients With Precapillary Pulmonary Hypertension During 30h Exposure to 2500m

NCT03165019CompletedPrimary

Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.

NCT03165656CompletedPrimary

Right Ventricular Function at Rest in Highlanders/Lowlanders

NCT03172429CompletedPrimary

Cerebral Tissue Oxygenation in Highlanders/Lowlanders

NCT03165032CompletedPrimary

Right Ventricular Function During Exercise in Highlanders/Lowlanders

NCT01621061CompletedPrimary

Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders

NCT01530464Phase 1CompletedPrimary

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers

NCT01566565Phase 1CompletedPrimary

The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension

Showing all 19 trials

Research Network

Activity Timeline